Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on November 26, 2024 and the first day of trading is December 6, 2024.
The offering price was SEK 58 per ordinary share, corresponding to a total market value for all ordinary shares in Apotea of approximately SEK 6 billion. The total value of the offering amounts to approximately SEK 1,880 million, provided that the overallotment option is exercised in full.
Apotea is Sweden’s leading online pharmacy by market share with the goal of becoming the largest pharmacy in Sweden and hence also in the Nordics. With the widest assortment on the market, low prices and quick deliveries, the company facilitates everyday life for its three million active customers.
Vinge’s team primarily consisted of Jesper Schönbeck, Amanda Knutsson, Anna Svensson, Lorin Arabi, Karin Karsten and Elias Kröger (Capital Markets and Public M&A), Victor Ericsson, Emelie Svanberg, Ellenor Eckerborn och Marcus Svärd (Corporate Tax), Sam Seddigh and Emil Lindwall (Employment), Helena Rosén Andersson and Hilda Ivarsson (Permits), Fredrika Hjelmberg, Mario Saad and Siri Blomberg (Commercial agreements, IT and GDPR), Ian Jonson (Intellectual Property) and Sofia Haggren (Financing).
